Sunday 18 October 2026
Export APMD’s income statement to Excel — free account
Apnimed, Inc.
APMD
Apnimed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, up 380.1% from fiscal 2024. Insiders bought in the last twelve months.
17.76
0.49
−2.68%
Follow APMD
An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.
| Jun '26 | |
|---|---|
Revenue |
117.14 |
Cost of Revenue |
6.41 |
Gross Profit |
110.72 |
R&D Expenses |
57.43 |
SG&A Expenses |
30.00 |
Operating Income |
23.29 |
Non-operating Income/Expense |
140.89 |
| 164.18 | |
Income after Tax |
164.18 |
Net Income Common |
95.53 |
EPS (Basic) |
19.73 |
EPS (Diluted) |
(14.63) |
Shares (Basic, Weighted) |
4.77 |
Shares (Diluted, Weighted) |
18.50 |
Gross Margin |
94.53% |
EBIT Margin |
19.88% |
EBT margin |
140.16% |
Net Profit Margin |
81.56% |
Free Cash Flow Margin |
(71.50%) |
EBITDA |
23.32 |
EBIT |
23.29 |
EPS (Diluted, from Cont. Ops) |
(0.71) |
EPS (Diluted, Consolidated) |
(14.65) |
EPS (Diluted, from Disc. Ops) |
0.00 |
EPS (Basic, Consolidated) |
19.73 |
EPS (Basic, from Discontinued Ops) |
(14.43) |
EPS (Basic, from Continuous Ops) |
34.17 |
Income from Continuous Operations |
164.18 |
Income from Discontinued Operations |
(68.64) |
Consolidated Net Income/Loss |
95.53 |
EBITDA Margin |
19.91% |
Operating Cash Flow Margin |
(71.50%) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated 7 Oct 2026